Retro-anandamides, high affinity and stability cannabinoid receptor ligands
Novel retro-anandamides are presented which have high affinities for the cannabinoid CB1 and/or CB2 receptor sites. Further, most of the analogs exhibit greater metabolic stability than arachidonylethanolamide. The improved receptor affinity and selectivity and/or greater metabolic stability make these analogs therapeutically useful as medications in individuals and animals for treatment of pain, glaucoma, epilepsy, nausea associated with chemotherapy, as well as suppression of the immune system, enhancement of appetite and in treatment of certain mental disorders.
1. A compound of the formula:
or a physiologically acceptable salt thereof, wherein:
B is selected from C═O, and C═S;
A is NH;
R 1 is selected from n—C 5 H 10 D, n—C 6 H 12 D, n—C 7 H 14 D, and 1′1′-C(CH 3 ) 2 (CH 2 ) 5 CH 2 D, wherein D is selected from H, halogen, N 3 , NCS, OH, CN and —CH═CH—I;
R 2 is selected from H, CH 3 , and (CH 3 ) 2 ; and
R 3 is selected from CHE 2 , CH 2 E, CH═CH 2 , CH 2 OCH 3 , —C≡CH, —O(CH 2 )nCH 3 , —S(CH 2 )nCH 3 , —(CH 2 )nCH 2 E and
wherein E is halogen and n and m are each independently a number from 0 to about 7,
wherein X is selected from N and CH and Y and Z are each independently selected from (CH 2 ) p , O, N and S, and wherein p is a number from 0 to about 7,
wherein X, Y and Z are each independently selected from CH and N, and
wherein R4, R5 and R6 are each independently selected from hydrogen, halogen, N 3 , NCS, OCH 3 , CH 3 , CH 2 CH 3 , NO 2 , NH 2 and phenyl
with the proviso that,
if D is H, R 2 is H and B is C═O, then R3 cannot be a phenyl ring, an alkyl phenyl ring or a halogen substituted alkyl phenyl ring.
2. The compound of claim 1 wherein B is C═O.
3. The compound of claim 1 wherein:
B is C═O; and
R 3 is selected from CH 2 E, CH 2 OCH 3 , —C≡CH, —O(CH 2 )nCH 3 ,
wherein E is halogen and n and m are each independently a number from 0 to about 7,
wherein X is selected from N and CH and Y and Z are each independently selected from (CH 2 ) p , O, N and S, and wherein p is a number from 0 to about 7,
wherein X, Y and Z are each independently selected from CH and N, and
wherein R4, R5 and R6 are each independently selected from hydrogen, halogen, N 3 , NCS, OCH 3 , CH 3 , CH 2 CH 3 , NO 2 , NH 2 and phenyl.
4. A method of binding a compound to cannabinoid receptors in an individual or animal comprising administering to the individual or animal a pharmacological preparation comprising an effective amount of a compound having the formula:
or a physiologically acceptable salt thereof, wherein:
B is selected from C═O, and C═S;
A is NH;
R 1 is selected from n—C 5 H 10 D, n—C 6 H 12 D, n—C 7 H 14 D, and 1′1′-C(CH 3 ) 2 (CH 2 ) 5 CH 2 D, wherein D is selected from H, halogen, N 3 , NCS, OH, CN and —CH═CH—I;
R 2 is selected from H, CH 3 , and (CH 3 ) 2 ; and
R 3 is selected from CHE 2 , CH 2 E, CH═CH 2 , CH 2 OCH 3 , —C≡CH,
wherein E is halogen and n and m are each independently a number from 0 to about 7,
wherein X is selected from N and CH and Y and Z are each independently selected from (CH 2 ) p , O, N and S, and
wherein p is a number from 0 to about 7,
wherein X, Y and Z are each independently selected from CH and N, and
wherein R4, R5 and R6 are each independently selected from hydrogen, halogen, N 3 , NCS, OCH 3 , CH 3 , CH 2 CH 3 , NO 2 , NH 2 and phenyl
with the proviso that
if D is H, R 2 is H and B is C═O, then R3 cannot be a phenyl ring, an alkyl phenyl ring or a halogen substituted alkyl phenyl ring.
5. The method of claim 4 wherein:
B is C═O; and
R 3 is selected from CH 2 E, CH 2 OCH 3 , —C≡CH, —)(CH 2 )nCH 3 ,
wherein E is halogen and n and m are each independently a number from 0 to about 7,
wherein X is selected from N and CH and Y and Z are each independently selected from (CH 2 ) p , O, N and S, and wherein p is a number from 0 to about 7,
wherein X, Y and Z are each independently selected from CH and N, and
wherein R4, R5 and R6 are each independently selected from hydrogen, halogen, N 3 , NCS, OCH 3 , CH 3 , CH 2 CH 3 , NO 2 , NH 2 and phenyl.
6. The compound of claim 1 selected from one of the following structures:
7. The compound of claim 1 selected from one of the following structures:
8. The compound of claim 1 having the structure
9. The method of claim 4 wherein the compound is selected from one of the following structures:
10. The method of claim 4 wherein the compound is selected from one of the following structures:
11. The method of claim 4 wherein the compound is
12. The compound of claim 1 wherein R 3 is CH 2 OCH 3 .
13. The compound of claim 1 wherein B is C═O; R 2 is H; and R 3 is CH 2 OCH 3 .
14. The compound of claim 1 wherein B is C═O; R 2 is H; R 1 is C 5 H 10 ; D is H; and R 3 is CH 2 OCH 3 .
15. The method of claim 4 wherein in the compound R 3 is CH 2 OCH 3 .
16. The method of claim 4 wherein in the compound B is C═O; R 2 is H; and R 3 is CH 2 OCH 3 .
17. The method of claim 4 wherein in the compound B is C═O; R 2 is H; R 1 is C 5 H 10 ; D is H; and R 3 is CH 2 OCH 3 .
18. A compound of the formula:
or a physiologically acceptable salt thereof, wherein:
B is C═O;
A is NH;
R 1 is selected from n—C 5 H 10 D, n—C 6 H 12 D, n—C 7 H 14 D, and 1′1′-C(CH 3 ) 2 (CH 2 ) 5 CH 2 D, wherein D is selected from H, halogen, N 3 , NCS, OH, CN and —CH═CH—I;
R 2 is selected from H, CH 3 , and (CH 3 ) 2 ; and
R 3 is CH 2 OCH 3 .
19. The method of claim 4 wherein the compound selectively binds to CB1 receptors.
20. The method of claim 4 wherein the pharmacological preparation further comprises at least one member selected from an excipient, a vehicle, an adjuvant, a flavoring, a colorant, or a preservative and the compound is in isolated and substantially purified form.
21. The compound of claim 1 wherein the compound is in isolated and substantially purified form.
22. The compound of claim 18 wherein the compound is in isolated and substantially purified form.